Resistant Hypertension: Can Aprocitentan Be the Missing Piece? │ Pharmacology

UPDATE: On March 19, 2024, the U.S. Food and Drug Administration (FDA) approved aprocitentan (Tryvio) for treating patients with resistant hypertension.
This video looks into how aprocitentan works, the exciting findings from the PRECISION trial, Potential side effects, and important considerations.
References:
1. Clozel M. Aprocitentan and the endothelin system in resistant hypertension. Can J Physiol Pharmacol. 2022;100(7):573-583. doi:10.1139/cjpp-2022-0010
2. Schlaich MP, Bellet M, Weber MA, et al. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial [published correction appears in Lancet. 2023 Jan 28;401(10373):268]. Lancet. 2022;400(10367):1927-1937. doi:10.1016/S0140-6736(22)02034-7
3. Heidari Nejad S, Azzam O, Schlaich MP. Dual Endothelin Antagonism with Aprocitentan as a Novel Therapeutic Approach for Resistant Hypertension. Curr Hypertens Rep. 2023;25(10):343-352. doi:10.1007/s11906-023-01259-z
4. www.asn-online.org/education/...
Disclaimer: This RUclips video is not intended to provide diagnosis, treatment, or medical advice. The content provided in this video is for informational purposes only. Please consult with a physician or other healthcare professional regarding any medical or health-related diagnosis or treatment options. Information on this video should not be considered as a substitute for advice from a healthcare professional. The statements made about specific products are not to diagnose, treat, cure, or prevent disease.
#ResistantHypertension #Aprocitentan #PRECISION #BloodPressureControl #NewTreatment #medicaladvancements #medicalnews